Synopsis of recent research by authors named "Toshihiro Nanki"
- Toshihiro Nanki's recent research focuses primarily on the clinical effectiveness and safety of various therapeutic agents in treating rheumatic diseases, including studies on tocilizumab for COVID-19 pneumonia, abatacept for rheumatoid arthritis, and certolizumab pegol for rheumatoid arthritis in Japanese populations.
- His studies also explore disease mechanisms and predictive biomarkers in conditions like rheumatoid arthritis, emphasizing the relationship between lipid profiles and disease activity, alongside assessing the impact of immunosuppressive drugs on vaccine responses for patients with rheumatic diseases.
- Nanki's work includes nationwide epidemiological surveys and evaluations of diagnostic criteria for various autoimmune conditions, such as polyarteritis nodosa and antineutrophil cytoplasmic antibody-associated vasculitis, underscoring the need for improved diagnostic frameworks in the context of rheumatic diseases in Japan.